Načítá se...
Cardiac Myosin Activation for the Treatment of Systolic Heart Failure
Left ventricular systolic dysfunction is the hallmark pathology in heart failure with reduced ejection fraction. Increasing left ventricular contractility with beta-adrenergic receptor agonists, phosphodiesterase-3 inhibitors, or levosimendan has failed to improve clinical outcomes and, in some situ...
Uloženo v:
| Vydáno v: | J Cardiovasc Pharmacol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7779665/ https://ncbi.nlm.nih.gov/pubmed/33165138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FJC.0000000000000929 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|